New blood thinner may shield heart during artery procedure
NCT ID NCT02505399
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether ticagrelor, a newer antiplatelet drug, reduces heart muscle damage during a procedure called rotational atherectomy, which clears hardened arteries. 180 stable heart patients received either ticagrelor or standard clopidogrel before and after the procedure. Researchers measured troponin levels to see if ticagrelor better prevents tiny blood clots and debris from harming the heart.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ticagrelor
What this could lead to
If it works, this could show that ticagrelor better protects the heart during artery-clearing procedures, potentially reducing complications.
What could go wrong
This is a small, completed Phase 4 trial with 180 patients, so results may not apply broadly. Ticagrelor also carries a higher bleeding risk than clopidogrel.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinique Pasteur
Toulouse, Haute-Garonne, 31000, France
-
Fédération de Cardiologie CHU TOULOUSE
Toulouse, Haute-Garonne, 31059, France
-
Hospices civils de Lyon
Lyon, 69000, France
-
University Hospital
Nîmes, 30000, France